Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

http://www.wikidata.org/entity/Q33397545

about

Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.The challenges and the promise of molecular targeted therapy in malignant gliomas.A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.Therapeutic targeting of VEGF in the treatment of glioblastoma.Molecular-targeted agents combination therapy for cancer: developments and potentials.Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

P2860

Q30313117-C8757D05-9FFB-4885-A836-3FD27583A883 Q34001009-D8B3A799-D2F6-482A-9B14-D4359CBE0CDF Q35214534-CEF85FBD-B934-493F-A782-3338AD6AD31D Q36319721-C65F819E-3F12-49C5-B177-68D79208AC90 Q38033241-B2E6E96B-4EFE-4F94-85B2-76077D4CD222 Q38104670-4E044202-AF68-4E0C-9ADE-EF009B90A840 Q38233105-E72EB23A-D383-486B-A23A-0CCF16F9C145 Q49501093-2E176F29-00C6-4FEF-8DA9-34ACB9D8AB81 Q53522981-A9865B79-DB52-46CB-B67D-227C0E175A23

P2860

Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.

http://www.wikidata.org/entity/Q33397545

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@ast

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@en

type

label

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@ast

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@en

prefLabel

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@ast

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@en

P1433

Q33397545-9FBA46F2-F171-4D01-AEF4-4997DCF3D602

P1476

Q33397545-31037E0D-B498-4E97-BD41-1C909E78769B

P2093

Q33397545-4D7954BE-0B54-4ADE-90FD-22AEA4C8C2C8

Q33397545-53429C90-D4F3-46AE-BB5D-29753CA7A2E3

Q33397545-723422D5-0A57-49E5-B47D-36AF660C215E

Q33397545-7F0C94A4-3AD4-4D7D-BBE6-E8AF9FAE4980

Q33397545-98059004-80E4-4D04-8F57-ADFB6D612415

Q33397545-A034A7F9-DCCB-4AAD-8460-5148D9D45FC7

Q33397545-B571B2A0-D926-41A1-9B82-656910F2AA47

Q33397545-D1A3EBC6-1808-4FB8-B329-2A1544F74AE1

Q33397545-E19B4901-302A-4626-BC44-11A9B2974F4D

Q33397545-FE2E2B8E-8B30-46D1-8837-57B4F9DBC10C

P2860

Q33397545-08A1D576-5302-4CBA-B8F8-E2A7F7E4B65F

Q33397545-10CD1958-051D-4402-A322-F2A12C8FCE1E

Q33397545-246CD107-9103-4963-87DE-D75A3EC29F7E

Q33397545-37A79C58-FC04-4B51-AD6D-6B55AEB18C32

Q33397545-399E2B06-4F14-4B3C-84F3-A10FB56D0B3D

Q33397545-3A9F80B4-76D9-4660-B6ED-2B63B26D46C4

Q33397545-4AE6A0CE-5F00-4F56-86D1-F1EA450459C7

Q33397545-61F1BB4B-7A4D-462F-A053-9188497ED472

Q33397545-7006E990-9EB1-4541-90DD-B4F616ADEFAC

Q33397545-986A3FD9-99AF-42AF-B5A7-472DB7442FE5

P2888

Q33397545-DF9BFB3C-3717-403A-819A-1C98F6DB077A

P304

Q33397545-001F3535-D1A8-42E2-A4E1-129BB4D1AB96

P31

Q33397545-01423286-5000-491C-9765-F4BB646A8713

P356

Q33397545-D8F1EA6C-F6F5-4E3D-875F-1FB6789AA9C7

P433

Q33397545-72F46992-7C6C-4B83-A952-B3038A69FC82

P478

Q33397545-847C3C27-4A8A-4C0E-AF9A-0381BA3B0F6D

P50

Q33397545-6DAF025F-A5D1-4BC5-B6BF-C537B16E9AEE

P577

Q33397545-B6C11E2A-AA4C-42EC-833D-49D2116AA29B

P6179

Q33397545-08A440ED-176B-4057-98E9-6CB9FE59805A

P698

Q33397545-A566DF44-C83F-495B-9C21-AB3632808C38

P921

Q33397545-8C3252A5-3F86-48EB-8FF0-2F9828C49F10

P356

S00280-011-1754-1

P1433

Cancer Chemotherapy and Pharmacology

P1476

Pharmacokinetic drug interacti ...... in patients with glioblastoma.

@en

P2093

Andrea Maes

http://www.w3.org/2001/XMLSchema#string

Charles Conrad

http://www.w3.org/2001/XMLSchema#string

Clifford DiLea

http://www.w3.org/2001/XMLSchema#string

Jeremy Rich

http://www.w3.org/2001/XMLSchema#string

Jerry Huang

http://www.w3.org/2001/XMLSchema#string

Lotus Yung

http://www.w3.org/2001/XMLSchema#string

Margaret Dugan

http://www.w3.org/2001/XMLSchema#string

Timothy Cloughesy

http://www.w3.org/2001/XMLSchema#string

W K Alfred Yung

http://www.w3.org/2001/XMLSchema#string

William Mietlowski

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Review of the proliferation inhibitor everolimus.

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Dose-finding with two agents in Phase I oncology trials.

P2888

s00280-011-1754-1

P304

281-287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-011-1754-1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

David A Reardon

P577

2011-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009222974

http://www.w3.org/2001/XMLSchema#string

P698

21984222

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia